Document Detail


Usefulness of HFA-BDP for adult patients with bronchial asthma: randomized crossover study with fluticasone.
MedLine Citation:
PMID:  16939990     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In this randomized crossover study, 22 adult patients with moderate-to-severe persistent bronchial asthma were assigned to one of two groups. Patients in group 1 were administered fluticasone dry powder inhaler (DPI) for 8 weeks followed by a 2-week washout period, then hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) for 8 weeks. After a further 2-week washout, they were again administered fluticasone DPI for 8 weeks. Patients in group 2 were assigned HFA-BDP followed by fluticasone PII and finally HFA-BDP over the same time periods. In both groups, no significant difference was observed in use of beta2-agonists and symptom score between the treatment periods; however, markers of pulmonary function were significantly higher when on HFA-BDP versus fluticasone DPI. Significant increases of morning peak expiratory flow (PEF) (p < 0.01), forced expiratory volume in 1 second (FEV1.0) (p < 0.01), V50 (p < 0.05), and V25 (p < 0.01) were observed at 18 weeks in group 1, whereas there were significant decreases of V50 (p < 0.05) at 18 weeks in group 2. No significant difference was noted in circulating eosinophil count and serum ECP between the 2 treatments; however, ECP in induced sputum and nitric oxide in expired gas were significantly lower (p < 0.05 and < 0.01, respectively) when on HFA-BDP versus fluticasone DPI. HFA-BDP might be delivered to small airways more effectively than fluticasone DPI.
Authors:
Takahiko Horiguchi; Nobuyuki Hayashi; Daisuke Ohira; Hiroshi Torigoe; Tomohiro Ito; Masahiro Hirose; Yasushi Sasaki; Mamoru Shiga; Junichi Miyazaki; Rieko Kondo; Soichi Tachikawa
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The Journal of asthma : official journal of the Association for the Care of Asthma     Volume:  43     ISSN:  0277-0903     ISO Abbreviation:  J Asthma     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-30     Completed Date:  2006-10-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8106454     Medline TA:  J Asthma     Country:  United States    
Other Details:
Languages:  eng     Pagination:  509-12     Citation Subset:  IM    
Affiliation:
Department of Respiratory Medicine, Second Teaching Hospital, Fujita Health University School of Medicine, Nagoya, Aichi, Japan. kokyu-2@fujita-hu.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Agonists / administration & dosage,  adverse effects
Adult
Aerosol Propellants*
Androstadienes / adverse effects,  therapeutic use*
Anti-Asthmatic Agents / adverse effects,  therapeutic use*
Anti-Inflammatory Agents / adverse effects,  therapeutic use*
Asthma / drug therapy*
Beclomethasone / adverse effects,  therapeutic use*
Bronchodilator Agents / adverse effects,  therapeutic use*
Cross-Over Studies
Drug Combinations
Drug Therapy, Combination
Female
Humans
Hydrocarbons, Fluorinated / adverse effects,  therapeutic use*
Male
Medical Records
Metered Dose Inhalers
Middle Aged
Particle Size
Peak Expiratory Flow Rate / drug effects
Chemical
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Aerosol Propellants; 0/Androstadienes; 0/Anti-Asthmatic Agents; 0/Anti-Inflammatory Agents; 0/Bronchodilator Agents; 0/Drug Combinations; 0/Hydrocarbons, Fluorinated; 431-89-0/HFA 134a; 4419-39-0/Beclomethasone; 90566-53-3/fluticasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of the clinical efficacy of salmeterol and sustained-release tulobuterol (patch) on inade...
Next Document:  What predicts change in pulmonary function and quality of life in asthma or COPD?